Akiyama, Yukinori <br/><br/>
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.  [electronic resource] 

 -  World neurosurgery  May 2018 
 - e508-e514 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1878-8769 
<br/><br/><label>Standard No.: </label>10.1016/j.wneu.2018.02.070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Brain Neoplasms--drug therapy<br/>Carmustine--administration & dosage<br/>Combined Modality Therapy<br/>Cranial Irradiation--adverse effects<br/>Craniotomy<br/>Cysts--etiology<br/>Dacarbazine--administration & dosage<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Drug Evaluation<br/>Drug Implants<br/>Drug Synergism<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--surgery<br/>Neurosurgical Procedures<br/>Postoperative Hemorrhage--etiology<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Temozolomide<br/>Treatment Outcome<br/>Tumor Microenvironment